OMNICELL, INC.

Listed Company

OMCLCIK 0000926326NasdaqLarge AcceleratedElectronic ComputersDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.18B

Net Income

$2.05M

Total Assets

$1.97B

Equity

$1.23B

Shares Out

45.44M

Op. Cash Flow

$127.30M

Business

OMNICELL, INC. designs and delivers medication management infrastructure to automate and optimize pharmacy and nursing workflows across care settings. It offers robotics and automated dispensing systems, IV compounding solutions, software workflows and cloud-based platforms, SaaS and Expert Services, patient engagement and medication adherence products, consumables, and professional and technical services. Its operations are organized around market categories including Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B, Ambulatory Care, Inventory Optimization, and EnlivenHealth. Omnicell primarily sells direct in the United States and Canada, with direct teams in select European and Australian markets and distributor channels elsewhere, and also sells through group purchasing organizations and government contracts.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	1,185	1,112	1,147	1,296	1,132
Cost of revenues	681	641	650	707	577
Gross profit	503	471	497	589	555
Research and development	89	90	97	105	76
Selling, general, and administrative	410	380	435	486	389
Total operating expenses	498	471	532	591	465
Income (loss) from operations	5	337,000	−35	−2	90
Interest and other income (expense), net	6	25	15	−130,000	−24
Income (loss) before income taxes	11	26	−20	−2	66
Provision for income taxes	9	13	263,000	−8	−12
Net income (loss)	2	13	−20	6	78
Basic (in dollars per share)	0.04	0.27	−0.45	0.13	1.79
Diluted (in dollars per share)	0.04	0.27	−0.45	0.12	1.62
Basic (in shares)	46	46	45	44	43
Diluted (in shares)	46	46	45	46	48

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	197	369	468	330	349
Accounts receivable and unbilled receivables, net of allowances of $8,868 and $6,645, respectively	217	256	252	299	241
Inventories	101	89	110	148	120
Prepaid expenses	34	26	26	27	22
Other current assets	132	75	72	77	48
Total current assets	680	815	928	882	781
Property and equipment, net	120	113	109	94	71
Long-term investment in sales-type leases, net	61	53	43	33	—
Operating lease right-of-use assets	24	26	25	38	49
Goodwill	738	735	736	734	739
Intangible assets, net	170	188	211	243	278
Long-term deferred tax assets	58	57	33	22	16
Prepaid commissions	53	55	52	59	64
Other long-term assets	70	79	90	105	128
Total assets	1,975	2,121	2,227	2,211	2,142
Accounts payable	44	52	45	63	72
Accrued compensation	57	60	52	73	71
Accrued liabilities	204	168	149	173	133
Deferred revenues	172	141	122	119	112
Convertible senior notes, net	0	174	0	0	488
Total current liabilities	477	596	368	428	876
Long-term deferred revenues	63	76	59	37	20
Long-term deferred tax liabilities	683,000	1	2	2	52
Long-term operating lease liabilities	25	31	34	39	40
Other long-term liabilities	10	7	6	7	8
Convertible senior notes, net, noncurrent	168	166	570	567	0
Total liabilities	743	878	1,038	1,081	996
Commitments and contingencies (Note 14)	—	—	—	—	—
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0	0	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 57,833 and 56,665 shares issued; 45,027 and 46,382 shares outstanding, respectively	58,000	57,000	56,000	55,000	54,000
Treasury stock at cost, 12,806 and 10,283 shares outstanding, respectively	−368	−290	−290	−290	—
Additional paid-in capital	1,224	1,168	1,122	1,047	1,025
Retained earnings	385	383	370	391	369
Accumulated other comprehensive loss	−9	−17	−13	−17	−8
Total stockholders equity	1,232	1,243	1,189	1,130	1,147
Total liabilities and stockholders equity	1,975	2,121	2,227	2,211	2,142

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	79	82	87	87	73
Loss on disposal of assets	488,000	978,000	3	678,000	433,000
Share-based compensation expense	45	39	55	68	53
Deferred income taxes	−1	−15	−11	−37	−3
Amortization of operating lease right-of-use assets	8	8	8	12	12
Impairment and abandonment of operating lease right-of-use assets related to facilities	0	0	10	9	0
Impairment of external-use software development costs	599,000	0	0	—	—
Impairment of certain long-lived assets	0	0	1	0	0
Inventory write-down	0	5	0	0	—
Amortization of debt issuance costs	3	4	4	4	3
Gain on extinguishment of convertible senior notes, net	0	−8	0	0	—
Accounts receivable and unbilled receivables	41	−5	49	−60	−41
Inventories	−11	16	38	−30	−26
Prepaid expenses	−8	24,000	1	−5	−6
Other current assets	−774,000	9	−7	6	3
Investment in sales-type leases	−10	−10	−10	−15	3
Prepaid commissions	2	−2	7	4	—
Other long-term assets	4	2	2	5	−3
Accounts payable	−9	7	−18	−8	29
Accrued compensation	−4	9	−21	2	12
Accrued liabilities	−19	14	−10	17	35
Deferred revenues	16	29	24	24	24
Operating lease liabilities	−12	−11	−11	−14	−13
Other long-term liabilities	2	900,000	−401,000	−699,000	−15
Net cash provided by operating activities	127	188	181	78	232
Asset acquisition	−2	0	0	—	—
External-use software development costs	−18	−16	−14	−13	—
Purchases of property and equipment	−40	−36	−41	−48	−29
Net cash used in investing activities	−60	−53	−55	−59	−412
Payments for debt issuance costs for revolving credit facility	0	0	−3	0	0
Repayment of convertible senior notes due 2025	−175	0	0	0	—
Proceeds from issuance of convertible senior notes, net of issuance costs	0	166	0	0	0
Partial repurchase of convertible senior notes	0	−391	0	—	—
Purchase of convertible note hedge	0	−40	0	0	0
Proceeds from sale of warrants	0	25	0	0	0
Partial unwind of convertible note hedge and warrants	0	−727,000	0	0	—
Proceeds from issuances under stock-based compensation plans	17	13	23	40	67
Employees taxes paid related to restricted stock units	−8	−5	−7	−14	−16
Common stock repurchases	−78	0	0	−52	0
Change in customer funds, net	25	−4	11	5	−4
Net cash provided by (used in) financing activities	−218	−236	23	−21	47
Effect of exchange rate changes on cash and cash equivalents	4	−2	−1	−944,000	−974,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	−148	−102	148	−3	−134
Cash paid for interest	2	2	1	1	2
Unpaid purchases of property and equipment	2	1	877,000	892,000	883,000
Excise tax payable on common stock repurchases	388,000	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro